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Background: Androgen deprivation therapy (ADT) in localized prostate cancer improves overall survival and is
recommended by National Comprehensive Cancer Network guidelines in certain situations. However, ADT is without
benefit in other situations and can actually cause harm. This study examines recent trends in the ADT use and
quantifies the cost of guideline-discordant ADT.
Patients and methods: Patients, aged 66–80 years, in the Surveillance Epidemiology and End Results-Medicare
database with non-metastatic prostate cancer diagnosed between 2004 and 2007 were included for analysis. Prostate-
specific antigen, Gleason score, and stage were used to define D’Amico risk categories. Logistic regression was used
to examine factors associated with guideline-discordant ADT. Annual direct cost was estimated using 2011 Medicare
reimbursement for ADT.
Results: Of 28 654 men included, 12.4% received guideline-discordant ADT. In low-risk patients, 14.9% received
discordant ADT, mostly due to simultaneous ADT with radiation. Discordant use was seen in 7.3% of intermediate and
14.9% of high-risk patients, mostly from ADT as primary therapy. The odds of receiving guideline-discordant ADT
decreased over time (2007 versus 2004; OR 0.69; 95% CI 0.62–0.76). The estimated annual direct cost from
discordant ADT is $42 000 000.
Conclusion: Approximately one in eight patients received ADT discordant with published guidelines. Elimination of
discordant use would result in substantial savings.
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introduction
Prostate cancer affects ∼240 000 men each year in the United
States, and 81% will present with a localized and potentially
curable disease [1]. This cancer disproportionately affects the
Medicare population with 62% of all cases being diagnosed in
those of age 65 years or older [2]. It is common practice to
categorize patients based on clinical stage, Gleason score, and
the prostate-specific antigen (PSA) level into low-,
intermediate, and high-risk diseases [3]. This risk grouping
allows for treatment recommendations based on cancer
aggressiveness, including for some men no treatment [4].
There is increasing recognition of overtreatment in prostate
cancer including the use of androgen deprivation therapy
(ADT) in settings where it is not clinically indicated [5–7].
ADT has a well-studied and established role in localized
prostate cancer treatment. For men with intermediate or high-
risk disease treated with external beam radiation therapy (RT),
multiple randomized trials have demonstrated that adding
ADT significantly improves overall survival compared with RT
alone, and ADT is currently recommended by the National
Comprehensive Cancer Network (NCCN) guidelines in this
setting [8–13]. These guidelines do not recommend the use of
ADT with RT in low-risk cancer, the addition of ADT to
prostatectomy or ADT after brachytherapy. Further, ADT as
primary therapy (without surgery or radiation) has been found
to have no significant benefit when compared with no
treatment, and is not recommended for patients in any risk
category [14]. An important concern in guideline-discordant
uses of ADT is the potential harm to the patient without clear
benefit, as incident diabetes, cardiovascular disease, fractures,
mental health conditions and other health problems have all
been associated with ADT [15–24].
Previous research demonstrated that in the Medicare
population, use of ‘inappropriate’ ADT dramatically decreased
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after a Medicare policy change in 2004–2005 reduced the
financial incentive to physicians for providing ADT [6]. The
addition of PSA and Gleason score information to SEER-
Medicare starting in 2004 allowed for quantification of
guideline discordant ADT use by risk group, which previously
was impossible with SEER-Medicare studies including the
prior publication. The goal of the current study is to examine
recent patterns of ADT use, quantify guideline concordant
versus discordant use by risk group, and to estimate the
financial burden of discordant use on Medicare.
patients and methods
data source
This study was exempted by the University of North Carolina Institutional
Review Board. We used the Surveillance, Epidemiology, and End Results
cancer registry linked to Medicare claims data (SEER-Medicare) to identify
patients diagnosed with prostate cancer. SEER-Medicare is widely used to
examine patterns of care in the over 65-year-old population [25].
patient selection
We included men diagnosed with clinically localized prostate cancer
between 2004 and 2007 with no other malignancies and excluded men in
whom the diagnosis was first made on the death certificate or autopsy. The
year cutoffs were used as PSA, and Gleason score were not available in
SEER-Medicare before 2004, precluding risk stratification, and 2007 was
the most recent year with available data. To allow for the assessment of
baseline comorbidity and initial treatment, we excluded men not
continuously enrolled in Medicare part A and B and those enrolled in a
HMO, for 1 year before and after diagnosis. This resulted in 54 703
patients considered potentially eligible for inclusion.
We further restricted the cohort by excluding patients over age 79 as the
optimal treatment strategy in this population is unclear (N = 8879). Patients
with locally advanced disease who are unlikely curable (T3b-T4, lymph
node positive) were also excluded (N = 1088) as were patients with missing
information for risk stratification (N = 10 563) or other important variables
(N = 1021). We restricted the analysis to African American and Caucasian
patients due to the small numbers of patients in other racial groups
(N = 4498). This resulted in a final cohort of 28 654 patients.
outcome and control variables
We used SEER patient-level data for the year of diagnosis and to categorize
patients into D’Amico risk groups: low risk (clinical T stage T1-T2a,
Gleason score ≤6, and PSA ≤10 ng/ml), intermediate risk (T2b, or Gleason
score 7, or PSA >10 and ≤20 ng/ml), and high risk (T2c or T3a, or PSA
>20 ng/ml, or Gleason score ≥8) [3]. SEER also provided data on race, age,
marital status, a census tract measure of socioeconomic status (education),
SEER region, and population density of the patient’s residence (urban
versus rural).
Treatment received was assessed using Current Procedural Technology/
Healthcare Common Procedure Coding System (CPT/HCPCS) codes in
Medicare data to identify prostatectomy, RT, brachytherapy, and ADT
received within 12 months of diagnosis (supplementary Table S1, available
at Annals of Oncology online). Medicare also provided data on an
individual level socioeconomic measure (Medicaid dual-eligibility), and
claims from the 12 months before prostate cancer diagnosis to calculate a
modified Charlson comorbidity index score validated specifically in claims
data, the National Cancer Institute Combined Index score [26].
According to the NCCN guidelines, discordant ADT included ADT as
primary therapy in all risk groups and its use with RT in low-risk disease.
The use of ADT before brachytherapy was considered concordant because
it is often used to downsize a large prostate to facilitate brachytherapy;
however, ADT after brachytherapy has no clear benefit (discordant). In
addition, ADT given before prostatectomy was guideline discordant, as
multiple randomized trials have demonstrated no benefit [27–29]. In order
to be conservative, we categorized ADT after prostatectomy as ‘guideline-
concordant’ because these patients may have had a biochemical recurrence.
statistical and cost analysis
We present descriptive statistics for the initial treatment received by
patients stratified by risk group. Bivariate and multivariate logistic
regression models were used to examine the potential association between
covariates and guideline-discordant ADT as the dependent variable.
Covariates included risk group, race (Caucasian or African American), age
at diagnosis (66–69, 70–74, 75–79 years), year of diagnosis, marital status,
comorbidity score (stratified by the median value of 0), census-tract
education, Medicaid eligibility, SEER region, and population density (urban
versus rural). All tests were two sided and reported with confidence
intervals, with P < 0.05 considered statistically significant. Analyses were
carried out with SAS 9.2 (Cary, NC).
Direct cost estimates were calculated based on the cost of ADT from the
Medicare code J9217 (which accounts for most of Medicare’s ADT claims)
in the fourth quarter of 2011. This reported cost of $221.07 was multiplied
by the estimated yearly incidence of localized prostate cancer in the over
65-year-old population as provided by SEER cancer statistics [1], by the
proportion of this population receiving discordant ADT based on findings
from this study, and then by an average duration of ADT. We considered
ADT durations of 6 months, 1 year, and 2 years in the cost estimates, with
1 year used as the base estimate. Additionally, we examined the cost from
discordant ADT use specifically in low-risk men, as these patients may not
need any treatment at all.
results
The baseline characteristics of the cohort are listed in Table 1.
Approximately one-third of patients were in each risk group:
low, intermediate, and high. Overall, 11.2% of the cohort was
African American, and 67.8% had a low comorbidity score.
Table 2 shows the frequency of guideline-discordant and
concordant ADT stratified by risk group. Overall, 12.4% of
patients received guideline-discordant ADT, including 14.9% of
low-risk patients, 7.3% of intermediate risk patients, and 14.9%
of high-risk patients. Most of the guideline-discordant use in
high-risk (1228/1456 patients) and intermediate risk men (492/
689) was due to ADT as primary therapy. On the other hand,
the majority of guideline-discordant ADT in the low-risk
group was due to its addition to external beam RT or after
brachytherapy (1040/1405).
Bivariate and multivariate logistic regression results are
presented in Table 3. On multivariate analysis, patients who
were older [Odds ratio (OR) 1.33 for age 70–74 years, OR 2.32
for age 75–79 years], or had a higher baseline comorbidity
(OR 1.32) were significantly more likely to receive guideline-
discordant ADT. African American race was borderline
significantly associated with receipt of guideline-discordant
ADT. There was a decrease in guideline discordant use from
2004 to 2007(OR 0.69, for 2007 versus 2004).
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The direct cost to Medicare from discordant ADT is
estimated at $42 000 000 per year if we conservatively assume
an average duration of therapy of 1 year. The cost changes
proportionally if we assume shorter or longer durations of
ADT (Figure 1). The direct cost from the low-risk group alone
is $16 000 000 per year assuming an average duration of 1 year
of therapy.
discussion
In this population-based study of a recent cohort of men with
localized and potentially curable (non-metastatic, not locally
advanced) prostate cancer, we found that approximately one in
eight (12.4%) received guideline-discordant ADT within the
first year after diagnosis. We were able to further examine the
source of guideline-discordant use based on risk-based
subgroups and found that in intermediate and high-risk
patients the source of guideline-discordance was mostly due to
ADT use as primary therapy. On the other hand, in the low-
risk population, the majority of guideline-discordance was due
to ADT given with radiation. This study is unique as the first
to quantify the contemporary patterns of discordant ADT use
based on published guidelines, which was not possible
previously due to lack of PSA and Gleason information in
SEER. This discordant use of ADT results in a large
expenditure to Medicare.
While ADT has demonstrated efficacy in prostate cancer
treatment, there are also well-described long-term side-effects.
Keating et al. [17] have shown in a population-based study of
veterans that ADT is associated with a 28% increase in the risk
of incident diabetes and an ∼20% increased risk in vascular
morbidity, including coronary artery disease, stroke, and
myocardial infarction [17]. A SEER-Medicare study found an
increase in the risk of bone fractures in men receiving ADT
[18]. Additionally, there have been other published findings on
a range of adverse effects, including increased anemia,
decreased vitality and sexual function, worsening of cognition
and mood, as well as increased obesity and changes in body fat
redistribution [21–24].
Table 2. Frequency of guideline-discordant versus concordant ADT
according to NCCN guidelines by risk group for men with localized
prostate cancer
Discordant N (%) Concordant N (%)
Low risk (N = 7404) 1405 (14.9) 7999 (85.1)
No ADT 7412 (78.8)
ADT only 309 (3.3)
ADT + RT 722 (7.7)
ADT + BTa 318 (3.4) 562 (6.0)
ADT + surgeryb 56 (0.6) 25 (0.3)
Intermediate risk (N = 8189) 689 (7.3) 8763 (92.7)
No ADT 6331 (67.0)
ADT only 492 (5.2)
ADT + RT 1644 (17.4)
ADT + BTa 66 (0.7) 650 (6.9)
ADT + surgeryb 131 (1.4) 138 (1.5)
High risk (N = 8687) 1456 (14.9) 8342 (85.1)
No ADT 4470 (45.6)
ADT only 1228 (12.5)
ADT + RT 2810 (28.7)
ADT + BTa 40 (0.4) 730 (7.4)
ADT + surgeryb 188 (1.9) 332 (3.4)
aADT is concordant when used before brachytherapy (e.g. for prostate
downsizing), but discordant after brachytherapy. Combination
brachytherapy with external beam radiation is considered as external beam
radiation and consistent with clinical practice and the NCCN guidelines.
bADT is concordant when used after surgery (e.g. for possible recurrence)
but discordant before surgery.
ADT, androgen deprivation therapy; RT, radiotherapy; BT, brachytherapy.
Table 1. Patient characteristics of men with localized prostate cancer in







Caucasian 25 445 (88.8)
African-American 3209 (11.2)
Age at diagnosis (years)
66–69 9708 (33.9)








Married 20 701 (72.2)
Not married/unknown 7953 (27.8)
NCI comorbidity index score
0 19 413 (67.8)
>0 9241 (32.2)












West 10 693 (37.3)
Residence
Rural 4417 (15.4)
Urban 24 237 (84.6)
Geographic regions are Northeast (Connecticut, New Jersey), South
(Atlanta, Rural Georgia, Kentucky, Louisiana), Central (Detroit, Iowa,
Utah, New Mexico), and West (California, Seattle, Hawaii).
NCI, National Cancer Institute; HS, high school.
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These important side-effects raise particular concern for the
ADT use in situations where it has no proven benefit. Multiple
randomized trials examining the addition of ADT to
prostatectomy have failed to show improvements in disease
control or survival [30–33]. Equally, primary ADT has no
demonstrated benefit in localized prostate cancer compared
with no treatment [14], and in two randomized trials primary
ADT resulted in worse survival compared with RT [34, 35].
Further, while ADT when added to RT has been shown to
improve overall survival in randomized trials for men with
intermediate and high-risk cancers, no clear benefit has been
shown when ADT is added to RT for low-risk disease [8–10,
13, 36, 37]. The ADT use in these clinical situations is not
supported by existing literature and is discordant with
published NCCN guidelines.
It is likely that in men with low-risk disease, the use of ADT
either as primary therapy or when added to RT represents
overtreatment. The issue of overtreatment in prostate cancer
recently has gained more attention, and applies especially to
low-risk (slow growing) disease [5]. Given the overwhelmingly
good outcomes of men with low-risk disease receiving RT, BT,
prostatectomy, and even on active surveillance, the addition of
ADT in these patients is more likely to harm than benefit the
patient.
However, in high-risk and some intermediate risk men,
guideline-discordant ADT may represent undertreatment of a
potentially curable malignancy, possibly due to inadequate
referral patterns or perceived patient frailty [38]. There is an
emerging literature describing the undertreatment of elderly
patients with aggressive cancers. For example, elderly patients
with colorectal cancer are less likely to receive adjuvant
chemotherapy for potentially curable disease, while elderly
patients with head and neck cancer receive less total radiation
than younger patients [39, 40]. Our data suggest that this
finding may also apply in elderly patients with high-risk
prostate cancer. However, the important difference in prostate
compared with other cancers is that overtreatment within
prostate cancer is possible as well as undertreatment. Further
complicating this is that undertreatment uses an agent that
can actually be harmful to the patient. Examination of failure
to use ADT in guideline concordant situations (e.g.
intermediate and high-risk men receiving RT) was not done
in this analysis but could be an important issue to examine
in future studies.
We examined multiple demographic factors to determine
which men were more likely to receive guideline-discordant
therapy. In addition to older age, men with more
comorbidities were more likely to receive guideline-discordant
ADT. This may be due to a desire from physicians and
patients to ‘do something’ for a diagnosed prostate cancer,
when in fact their competing causes of mortality are higher
than in younger and healthier patients [41, 42]. In this study,
there was an encouraging finding of a declining rate of
guideline-discordant ADT from 2004 to 2007, though there
remained significant use of guideline-discordant ADT as
recently as 2007.
In the current era of large increases in healthcare spending
and with ongoing national discussions about the long-term
fiscal viability of Medicare, we felt it was informative to make
a direct estimate of the cost outlays of this therapy to the
Medicare program. Conservatively assuming an average
duration of 1 year of ADT, the direct cost from guideline-
discordant ADT use is $42 000 000 per year. Importantly, our
analysis was based on the cost of ADT alone and did not
include potential costs such as facility charges for the
Table 3. Logistic regression models of guideline-discordant ADT in
localized prostate cancer
Bivariate Multivariate
Covariate OR 95% CI OR 95% CI
Risk group
Low – – – –
Intermediate 0.45 0.41–0.49 0.42 0.38–0.47
High 0.99 0.92–1.08 0.85 0.78–0.92
Race
Caucasian – – – –
African-American 1.38 1.25–1.53 1.12 1.00–1.26
Age at diagnosis (years)
66–69 – – – –
70–74 1.33 1.21–1.45 1.33 1.21–1.46
75–79 2.26 2.07–2.48 2.32 2.11–2.54
Year of diagnosis
2004 – – – –
2005 0.88 0.80–0.97 0.89 0.80–0.98
2006 0.78 0.71–0.86 0.78 0.71–0.86
2007 0.67 0.61–0.74 0.69 0.62–0.76
Marital status
Married – – – –
Not married/unknown 1.55 1.44–1.67 1.35 1.25–1.46
NCI comorbidity index score
0 – – – –
>0 1.48 1.38–1.59 1.32 1.23–1.42
Proportion of non-HS graduates in census tract
0–25% – – – –
26–50% 1.16 1.04–1.29 1.05 0.94–1.17
51–75% 1.34 1.21–1.48 1.16 1.04–1.29
76–100% 1.72 1.56–1.91 1.31 1.18–1.47
State Medicaid dual-eligibility
No – – – –
Yes 2.15 1.94–2.39 1.73 1.55–1.94
Geographic region
Northeast – – – –
South 1.41 1.27–1.56 1.26 1.13–1.41
Central 1.02 0.91–1.14 0.94 0.84–1.06
West 0.94 0.86–1.04 0.94 0.85–1.04
Residence
Rural – – – –
Urban 0.67 0.61–0.73 0.75 0.68–0.84
Geographic regions are Northeast (Connecticut, New Jersey), South
(Atlanta, Rural Georgia, Kentucky, Louisiana), Central (Detroit, Iowa,
Utah, New Mexico), and West (California, Seattle, Hawaii).
Multivariable analysis adjusted for: risk group, race, age, year of diagnosis,
marital status, NCI comorbidity index, measure of education by census
tract, Medicaid dual-eligibility, geographic region, and population density.
OR, odds ratio; CI, confidence interval; NCI, National Cancer Institute; HS,
high school.
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appointment or the cost of long-term complications due to
ADT use. In low-risk patients for whom active surveillance is
a potential management option, the cost from discordant
ADT is $16 000 000. On the other hand, for intermediate and
high-risk patients, forgoing ADT alone (discordant) and
instead pursuing surgical or radiation treatment may actually
increase utilization and direct costs to Medicare. However,
surgical and radiation treatments for aggressive prostate
cancers have a curative potential and have been found to be
cost effective, while ADT alone provides no proven
benefit [43].
There are several limitations to this analysis. Medicare data
may be subject to misclassification and the potential exists for
incorrect treatment assignment. However, SEER-Medicare is
commonly used and has established methodology for assessing
patterns of care [44–46], and the large numbers of patients
allow stable estimates of treatment patterns. Also, as the
treatment decision-making process is complex, we do not have
information regarding why guideline discordant therapy was
given. In some patients, there could be extenuating
circumstances leading to guideline discordant but not
‘inappropriate’ therapy. However, NCCN guideline
concordance is an established quality of care indicator [47],
and our finding that one in eight Medicare patients received
guideline-discordant ADT is concerning.
In summary, this study demonstrated in a recent cohort of
Medicare patients that one in eight men over the age of 65
with localized prostate cancer received ADT discordant with
published practice guidelines. Primary ADT, and simultaneous
ADT with radiation in low-risk cancer, are significant sources
of guideline discordant use. The ADT use in these settings has
no proven benefit but has well-established potential harms, and
results in significant costs to Medicare.
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